Consulter en ligne

Suggestions

Du même auteur

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.

Archive ouverte | Phillips, T. J. | CCSD

International audience. Purpose: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696) evaluated glofitam...

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Archive ouverte | Hutchings, M. | CCSD

International audience. PURPOSEGlofitamab is a T-cell–engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated...

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Archive ouverte | Bishop, M. R. | CCSD

International audience. BACKGROUNDPatient outcomes are poor for aggressive B-cell non-Hodgkin’s lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 ...

Chargement des enrichissements...